This review highlights the evolution of treatments for chronic myocardial ischemia, from standard medical and revascularization therapies to novel angiogenic approaches.
Standard therapies remain first-line for chronic myocardial ischemia; leaves open efficacy of angiogenic approaches pending prospective trials.
The presence of chronic myocardial ischemia signifies an imbalance between myocardial oxygen supply and demand that usually reflects the existence of advanced atherosclerotis coronary disease. Standard therapies for this condition that have evolved over the past 40 years include drugs primarily designed to reduce myocardial oxygen demand or improve flow through the existing vessels. In a select group of patients this approach is supplemented by coronary bypass grafting or coronary angioplasty. A new and currently evolving approach relies on stimulation of growth of new coronary vessels to improve myocardial perfusion that can be achieved either by the application of growth factors or mechanical means.
No takes yet. Share an insight, caveat, or question.
Simons et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: